EMG
KYMR icon

ETF Managers Group’s Kymera Therapeutics KYMR Stock Holding History

ETF Managers Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-26,611
Closed -$540K – 764
2022
Q2 		$540K Buy
+26,611
New +$622K 0.02% 419

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

ETF Managers Group's KYMR Position: Q3 2022 in Review

ETF Managers Group sold out of Kymera Therapeutics (KYMR) in Q3 2022, closing a stake of 26,611 shares — an estimated $540K sold.

ETF Managers Group first reported a position in KYMR in Q2 2022 and held it in 1 quarter. The position peaked at $540K in Q2 2022. 127 funds tracked by Wall St. Rank hold KYMR as of Q3 2022.

  • ETF Managers Group reported no remaining Kymera Therapeutics position as of Q3 2022 after selling out during the quarter.
  • ETF Managers Group sold 26,611 Kymera Therapeutics shares in Q3 2022, an estimated $540K.
  • ETF Managers Group first reported a position in Kymera Therapeutics in Q2 2022 and held it in 1 quarter.
  • ETF Managers Group's Kymera Therapeutics position peaked at $540K in Q2 2022.
  • 127 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2022.

Based on ETF Managers Group's 13F filing for Q3 2022, filed 14 Nov 2022.